KCM
ELEV

Kennedy Capital Management’s Elevation Oncology ELEV Stock Holding History

Kennedy Capital Management’s Portfolio ELEV Stock Details ELEV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-149,649
Closed -$284K – 670
2023
Q1 		$284K Hold
149,649
– – 0.01% 588
2022
Q4 		$142K Hold
149,649
– – ﹤0.01% 602
2022
Q3 		$169K Sell
149,649
-244
-0.2% -$307 0.01% 598
2022
Q2 		$210K Buy
149,893
+135,863
+968% +$341K 0.01% 588
2022
Q1 		$35K Sell
14,030
-1,455
-9% -$5.83K ﹤0.01% 599
2021
Q4 		$93K Buy
+15,485
New +$107K ﹤0.01% 609

Other funds holding ELEV

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
QUSVM
Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
ECM
ExodusPoint Capital Management New York $12.6B AUM 30.13% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Kennedy Capital Management's ELEV Position: Q2 2023 in Review

Kennedy Capital Management sold out of Elevation Oncology (ELEV) in Q2 2023, closing a stake of 149,649 shares — an estimated $284K sold.

Kennedy Capital Management first reported a position in ELEV in Q4 2021 and held it in 6 quarters. The position peaked at $284K in Q1 2023. 39 funds tracked by Wall St. Rank hold ELEV as of Q2 2023.

  • Kennedy Capital Management reported no remaining Elevation Oncology position as of Q2 2023 after selling out during the quarter.
  • Kennedy Capital Management sold 149,649 Elevation Oncology shares in Q2 2023, an estimated $284K.
  • Kennedy Capital Management first reported a position in Elevation Oncology in Q4 2021 and held it in 6 quarters.
  • Kennedy Capital Management's Elevation Oncology position peaked at $284K in Q1 2023.
  • 39 funds tracked by Wall St. Rank held Elevation Oncology as of Q2 2023.

Based on Kennedy Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.